Dendrite International and Skila Announce Agreement to Include the Skila Products in Dendrite's e-Pharma Initiative.

Buiness Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--April 13, 2000

Dendrite International, Inc. (NASDAQ/NMS:DRTE) today announced that it had entered into a definitive agreement with Skila, which allows it to integrate the Skila product in Dendrite's web based ePharma initiatives.

Skila's global healthcare intelligration(TM) technology and e-knowledge offerings would be included as an integral part of PharmaRep.com, Dendrite's pharmaceutical representative portal; MD-Connect.com, its destination portal sponsored by pharmaceutical companies for the use by medical practitioners, and Patient-Connect.com, its patient information portal that collects new patient data.

Skila provides a powerful engine to search the world's pharmaceutical publishing and news databases for current or historical information. In each of the three web based initiatives, Skila represents an important facility to allow patients, doctors and sales representatives to individually seek and retrieve information of special interest from the world's pharmaceutical press.

Dendrite will partner with Skila to market their Intelligration(TM) offering to the pharmaceutical industry on a global basis in a multi-year agreement. "The challenge facing our pharmaceutical clients continues to be their ability to bring prescribers back to their own product web-pages and other initiatives. We believe that we have an answer to that problem with the specialized capabilities and focused products of our destination portals, which effectively promote repeat visits. The combination of partners we have brought to this initiative indicates the breadth and depth of our commitment to use the power of the internet to unlock additional novel and effective tools that enhance and integrate with the traditional sales message delivered by pharmaceutical sales reps," said John Bailye, Dendrite Chairman and CEO.

Dendrite invested in this strategic relationship with Skila to enable them to accelerate implementation of Skila's growth strategy and expansion into new markets and services. Moish Tov, CEO of Skila said, "Specifically, the partnership with Dendrite will provide Skila with cross-marketing opportunities within the pharmaceutical markets as well as access to cutting-edge technology and automation to support the rapid growth in Skila's Global Healthcare Intelligence Platform(TM) users."

About Skila Intelligence

Skila intelligence is a concise visual map of the global healthcare market, which is created and delivered via the Global Healthcare Intelligence Platform(TM). Through a complex, proprietary process called Intelligration(TM), information from thousands of internal and external global sources is synthesized. The information is then filtered, tagged, matched, validated, indexed, organized and updated, transforming the massive amount of data into succinct tailored views of actionable business intelligence.

About Skila

Skila, Inc. is the leader in providing Internet-based business intelligence and e-knowledge solutions to pharmaceutical, medical device and biotechnology companies. Skila's team is composed of experienced professionals from the healthcare, information and technology arenas. The company's investors/partners include The Sprout Group, a venture capital affiliate of Donaldson, Lufkin and Jenrette (NYSE: DLJ) and Crosslink Capital, Inc. (formerly Omega Venture Partners). Skila is privately held and based in Mahwah, New Jersey with offices in Europe and Japan. More information on Skila and its solutions can be found on the World Wide Web at: http://www.skila.com.

ABOUT DENDRITE

As a leading global provider of highly specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986.

Headquartered in Morristown, New Jersey, Dendrite employs over 1300 people around the world. For more information, visit the Company's Web site at http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) we are exposed to risks associated with the Year 2000 (for example, (a) demand for our software products and services may decline before and after the Year 2000, (b) our Year 2000 remediation efforts may be unsuccessful and (c) we may incur material expenses in connection with any claim relating to Year 2000 compliance of our own products or the products of third parties); (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.